Tata Consumer Q2 net up 8 per cent; beats estimates

Tata Consumer on Friday beat Street estimates, reporting an almost 8% increase in net profit for the quarter ended September 2024 (Q2FY25) to Rs 364 crore, compared to Rs 338 crore in the same period last year. Analysts polled by Bloomberg had projected a net profit of Rs 343 crore for the quarter under review.

Revenue for the quarter grew nearly 13% year-on-year to Rs 4,214 crore, slightly below street estimates of Rs 4,340 crore. The company’s India beverage business grew by 3%, though it saw a 4% decline when excluding Organic India. Notably, the coffee segment recorded a 29% year-on-year revenue increase.

In the India foods segment, revenue rose by 28%, or 9% when excluding Capital Foods. The value-added salt portfolio showed strong momentum, growing by 26%, with rock salt achieving record volumes, according to the company.

Also Read Higher raw material prices may keep Nestle’s growth under pressure CNG prices to increase as APM gas supplies cut, yet CGD firms may take a hit DMart Q2 net profit up 5.8% to Rs 660 crore India proposes $1.1-billion retaliation against EU for extra steel duties

“Our India tea business was impacted by subdued category trends. Tata Starbucks reached the milestone of being the largest café operator by store count, with 457 stores across 70 cities,” said Sunil D’Souza, managing director and CEO of Tata Consumer.

Also ReadTravel and tourism deal activity globally posts drop of 11% YoY during Q1-Q3 2024, says GlobalData

On the operational front, earnings before interest, tax, depreciation, and amortisation (Ebitda) grew 12.5% year-on-year to Rs 841 crore, surpassing street estimates of Rs 626 crore. However, Ebitda margins slightly contracted by 10 basis points to 19.9% in Q2, down from 20% a year ago, primarily due to higher input costs for the India tea business, the company noted.

The international business achieved 7% revenue growth (5% in constant currency terms), with profitability improving by over 53% year-on-year.

Additionally, the company completed the merger of its wholly-owned subsidiaries in India—NourishCo, Tata Soulfull, and Tata Smart Foodz—during Q2, in line with its strategy to “simplify, synergise, and scale the business”, the company stated.

Shares of Tata Consumer closed at Rs 1,094.65 on Friday, up Rs 4.20 or 0.39% on the BSE.

 » Read More

Related Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

‘Pramerica Life targets Rs 3,000-crore GWP in FY26,’ Pankaj Gupta

Pramerica Life Insurance, a joint venture between subsidiaries of Piramal Capital and Housing Finance and US-based Prudential Financial Inc, aims to close FY26 with Rs 3,000 crore in gross written premium. In an interview with Narayanan V, managing director and CEO Pankaj Gupta discusses the products and distribution strategy. Excerpts: Life insurance premiums have been

Tata small cap fund: Targeting growth at reasonable valuations

Tata Small Cap Fund is a growth-oriented scheme in the Small Cap Fund category that has exhibited a noteworthy track record since its inception and has outpaced many of its prominent peers, thereby rewarding investors with superior risk-adjusted returns. Launched in November 2018, Tata Small Cap Fund aims to invest in stocks of companies that are in growth